Henrijette Richter
Managing Partner, Sofinnova Partners / Faculty at CBS Executive
Schools
- CBS Executive
Expertise
Links
Biography
CBS Executive
Henrijette Richter is one of our managing partners and an active member of the Capital Funds team, our flagship fund dedicated to early-stage biotechs and medtechs.
She joined Sofinnova in 2014, and her investments and board involvements include Mozart Therapeutics, Muna Therapeutics, Nitrase Therapeutics, Nodthera, Twentyeight-Seven Therapeutics, Asceneuron, Delinia (sold to Celgene), and iOmx Therapeutics.
Prior to Sofinnova, Henrijette was part of the team that founded Novo Seeds in 2007, and as an Investment Director, she was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO; ORPH), Avilex Pharma, EpiTherapeutics (sold to Gilead), and Lysogene (LYS, Euronext Paris).
Henrijette holds a combined Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen and Novo Nordisk A/S. She did her postdoctoral fellowship at the MIT Center for Cancer Research in Massachusetts.
Read about executive education
Other experts
Popular Courses
The Manchester Leadership Development Programme
Alliance Manchester Business School
Manchester, United Kingdom
Jul 1
Leading People and Teams
ESMT
Berlin, Germany
May 28
Private Equity: Investing and Creating Value
The Wharton School
Philadelphia, Pennsylvania, United States
Sep 8
Leading Strategic Growth and Change
Columbia Business School
New York, New York, United States
Jun 10
The Positive Leader: Deep Change and Organizational Transformation
Stephen M. Ross School of Business
Ann Arbor, Michigan, United States
Jun 23
Leading Digital Transformation
ESMT
Berlin, Germany
May 28
Looking for an expert?
Contact us and we'll find the best option for you.